Citations

Clear

6273 citation(s) found for "To, Andrew".

International Myeloma Society/International Myeloma Working Group Consensus Recommendations on the Definition of High-Risk Multiple Myeloma
Avet‐Loiseau, Hervé , Davies, Faith E. , Samur, Mehmet , Corre, Jill , D’Agostino, Mattia , Kaiser, Martin , Raab, Marc S. , Weinhold, Niels , Gutiérrez, Norma C. , Paiva, Bruno , Walker, Brian A. , Bustoros, Mark , Stewart, A. Keith , Hillengaß, Jens , Martínez‐López, Joaquín , Sperling, Adam S. , Dhodapkar, Madhav V. , Spencer, Andrew , Parekh, Samir , Sonneveld, Pieter , Bergsagel, P. Leif , Orlowski, Robert Z. , Mateos, María‐Victoria , Kumar, Shaji , Munshi, Nikhil C. , Martinez-Lopez, Joaquin , Bergsagel, P. Leif , Samur, Mehmet K , Kaiser, Martin F , Weisel, Katja C , Maura, Francesco , Walker, Brian A , Bustoros, Mark , Stewart, A Keith , Usmani, Saad , Hillengass, Jens , Chng, Wee Joo , Keats, Jonathan J , Martinez-Lopez, Joaquin , Sperling, Adam S , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur S , Bolli, Niccolo' , Ghobrial, Irene M , Dhodapkar, Madhav V , Jagannath, Sundar , Spencer, Andrew , Parekh, Samir , Bahlis, Nizar Jacques , Sonneveld, Pieter , Orlowski, Robert Z. , Mateos, María-Victoria , San-Miguel, Jesus , Anderson, Kenneth C , Moreau, Philippe , Kumar, Shaji K , Munshi, Nikhil C , Raab, Marc S , Martinez-Lopez, Joaquin , Paiva, Bruno , Davies, Faith E , Corre, Jill , Mattia, D'Agostino , Neri, Paola , Maura, Francesco , Usmani, Saad Z. , Chng, Wee Joo , Keats, Jonathan J. , Touzeau, Cyrille , Zhan, Fenghuang , Raje, Noopur , Cavo, Michèle , Bolli, Niccolò , Ghobrial, Irene M. , Jagannath, Sundar , Lonial, Sagar , Morgan, Gareth J. , Rajkumar, S. Vincent , Miguel, Jesús F. San , Anderson, Kenneth C. , Moreau, Philippe , Prósper, Felipe

Mayo Clinic

Journal of Clinical Oncology | June 9, 2025 | Volume: 43 | Issue: 24 | Pages: 2739-2751

10.1200/jco-24-01893 | PMID 40489728 Get It

Despite significant improvements in survival of patients with multiple myeloma (MM), outcomes remain heterogeneous, and a significant proportion of patients experience suboptimal outcomes. Importantly, traditional prognostic factors based on data from patients treated with older therapies no longer capture prognosis accurately in the contemporary era of novel triplet or quadruplet therapies. Therefore, risk stratification requires refinement in the context of available and investigational treatment options in routine practice and clinical trials, respectively. The current identification of high-risk MM (HRMM) in routine practice is based on the Revised International Staging System, which stratifies patients using a combination of widely available serum biomarkers and chromosomal abnormalities assessed via fluorescence in situ hybridization. In recent years, a substantial body of evidence concerning additional clinical, biological, and molecular/genomic prognostic factors has accumulated, along with new MM risk stratification tools and consensus reports. The International Myeloma Society, along with the International Myeloma Working Group, convened an Expert Panel with the primary aim of revisiting the definition of HRMM and formulating a practical and data-driven consensus definition, based on new evidence from molecular/genomic assays, updated clinical data, and contemporary risk stratification concepts. The Panel proposes the following Consensus Genomic Staging (CGS) of HRMM which relies upon the presence of at least one of these abnormalities: (1) del(17p), with a cutoff of >20% clonal fraction, and/or TP53 mutation; (2) an IgH translocation including t(4;14), t(14;16), or t(14;20) along with 1q+ and/or del(1p32); (3) monoallelic del(1p32) along with 1q+ or biallelic del(1p32); or (4) β2 microglobulin ≥5.5 mg/L with normal creatinine (<1.2 mg/dL).
The Impact of Social Determinants of Health on the Severity of Symptoms at Presentation and Discharge Disposition in Patients Undergoing Surgical Treatment of Cervical Myelopathy
Francois, Hendrick , Boateng, Atta , Jiang, Kelly , Johnson, Sarah E. , Smith, Kitara, Azad, Tej D., Ashayeri, Kimberly , Johnson, Sarah, Theodore, Nicholas , Weber-Levine, Carly , Mahapatra, Smruti , Davidar, A. Daniel , Hersh, Andrew M. , Alomari, Safwan , Bhimreddy, Meghana , Azad, Tej Deepak , Theodore, Nicholas

Mayo Clinic

Neurosurgery | June 9, 2025 | Volume: 98 | Issue: 1 | Pages: 211-220

10.1227/neu.0000000000003557 | PMID 40488526 Get It

BACKGROUND AND OBJECTIVES: Social determinants of health (SDOH), such as education, insurance, race, and income, significantly affect a patient's medical care and surgical outcomes. Additional studies characterizing the impact of SDOH on patients undergoing spine surgery are needed. Accordingly, this study evaluates the impact of SDOH on severity of symptoms at presentation and discharge disposition in patients undergoing surgical treatment of cervical myelopathy. METHODS: A retrospective single-center study identified adult patients undergoing surgical intervention for cervical myelopathy between 2016 and 2020. Cohort characteristics were collected from patient medical records. The t -test, Wilcoxon rank-sum, analysis of variance, Kruskal-Wallis, and χ 2 tests were used to compare variables when appropriate. Multivariable linear and logistic regression analyses were conducted for modified Japanese Orthopaedic Association (mJOA) and discharge disposition. All statistical analysis was performed in MATLAB R2022b (MathWorks, Natick, MA). RESULTS: A total of 480 patients were included in the study with a male predominance of n = 281 (59%) and a mean age of 62 ± 13 years. Racial demographics included 64% White (n = 308) and 36% Non-White (n = 172) patients. On univariable analysis, mJOA at presentation was significantly associated with employment status ( P < .01), annual income ( P < .01), education level ( P < .01), and insurance status ( P = .03). On multivariable analysis, annual income and education level continued to be significant predictors of presenting mJOA. On univariable analysis, discharge disposition was associated with body mass index ( P = .01), mJOA at presentation ( P < .01), employment status ( P = .05), annual income ( P < .01), education level ( P < .01), insurance ( P < .01), approach ( P < .01), and length of stay ( P < .01). On multivariable analysis, mJOA at presentation, education level, insurance, and approach continued to be significant predictors of discharge disposition. CONCLUSION: SDOH affect the severity of symptoms at presentation and discharge disposition in patients undergoing surgery for cervical myelopathy. Understanding these dynamics and uncovering additional SDOH are critical for enhancing surgical care and achieving equitable healthcare outcomes.
Stereotactic radiosurgery versus observation for intracranial low-grade dural arteriovenous fistulas
Becerril‐Gaitan, Andrea , Peesh, Pedram , Liu, Collin, Lee, Cheng-chia, Niranjan, Ajay , Lunsford, L. Dade , Wei, Zhishuo , Hoang, A, Sheehan, Jason P. , Dayawansa, Sam , Samanci, Yavuz, Starke, Robert M. , Ikeda, Go , Kano, Hideyuki , Wang, Qian , Welch, Babu G. , O’Con, Jennifer, Lanzino, Guiseppe, Brinjikji, Waleed , Hayakawa, M. , Gross, Bradley A. , Albuquerque, Felipe C , Lawton, Michael T., Kim, Louis J. , Alaraj, Ali , Winkler, Ethan A. , Chalouhi, Nohra , Bulters, Diederik , Durnford, Andrew , Satomi, Junichiro, Tada, Yoshiteru , Dijk, J. Marc C. van , Potgieser, Adriaan R. E., Laurent, Dimitri , Bahmani, Brigette, Zipfel, Gregory J. , Samancı, Yavuz , Tripathi, Manjul , Welch, Babu , Du, Rose , Lai, Rosalind , Gross, Bradley , Levitt, Michael R , Alaraj, Ali , van DijK, J Marc C , Osbun, Joshua W , Bulters, Diederik O , Yang, Huai‐Che , Peker, Selçuk , Abdelsalam, Ahmed , Kondziolka, Douglas , Bernstein, Kenneth, Ming, Ying, Liščák, Roman , May, Jaromír , Li, Wen , O’Con, Jennifer, Amin-Hanjani, Sepideh , Nguyen, Quang, Samaniego, Edgar A , Lai, Pui Man Rosalind , Derdeyn, Colin P. , Abla, Adib A. , Lawton, Michael T. , Kim, Louis J. , Levitt, Michael R. , Hoh, Brian L. , Chen, Ching‐Jen

Mayo Clinic

Journal of Neurology, Neurosurgery & Psychiatry | June 6, 2025 | Volume: 96 | Issue: 11 | Pages: 1117-1125

10.1136/jnnp-2024-335675 | PMID 40480804 Get It

Background Given the low haemorrhagic risk of intracranial low-grade dural arteriovenous fistulas (dAVFs), the benefits of routine intervention remain controversial. This study compares patient outcomes treated with stereotactic radiosurgery (SRS) versus conservative management. Method Multicentre retrospective analysis of the Consortium for Dural Arteriovenous Fistula Outcomes Research and the International Radiosurgery Research Foundation data. Inclusion criteria were (1) intracranial low-grade dAVF diagnosed by catheter-based angiography, (2) no prior dAVF-related haemorrhage and (3) management with upfront SRS (intervention group) or conservative management (observation group). The primary outcome was symptomatic improvement. Secondary outcomes included dAVF obliteration, up-conversion, haemorrhage, improvement and favourable modified Rankin Scale (mRS) at follow-up. Results 304 patients with a mean age of 56 years (SD 13.5) and a follow-up of 46.7 months (SD 45.5) were included. 135 (44.4%) were managed conservatively and 169 (55.6%) had upfront SRS. Compared with the observation group, symptomatic and mRS Score improvement (≥1-point decrease in baseline score) was more likely in the intervention group (95.1% vs 58.5%; OR=13.75 (5.61–33.69) and 37.0% vs 24.0%; OR=1.85 (1.09–3.15), respectively). These findings remained significant after multiple imputation and propensity score matching. Remaining outcomes were similar between groups. The all-cause mortality rate was 5.4% (n=16), unrelated to the dAVF or treatment. Five (3.0%) SRS-related complications were reported and resolved during the follow-up period. Conclusions SRS was associated with increased symptomatic and mRS Score improvement for low-grade dAVFs compared with conservative management. SRS had a low complication risk and did not appear to alter dAVF obliteration or haemorrhage. Future prospective trials on SRS as a first-line intervention for symptomatic low-grade dAVFs should be considered.
Progress in Pharmacogenomics Implementation in the United States: Barrier Erosion and Remaining Challenges
Smith, D. Max , Aquilante, Christina L. , Deverka, Patricia A. , Devine, Emily Beth , Dunnenberger, Henry M. , Empey, Philip E. , Hertz, Daniel L. , Monte, Andrew A. , Moyer, Ann M. , Pratt, Victoria M. , Saulsberry, Loren , Oni‐Orisan, Akinyemi , Douglas, Michael P , Devine, Beth , Dunnenberger, Henry M , Empey, Philip E , Hertz, Daniel L , Moyer, AM , Patel, Jai N , Pratt, Victoria M , Saulsberry, Loren , Scott, Stuart A , Voora, Deepak , Woodahl, Erica L , Whirl-Carrillo, Michelle , Oni-Orisan, Akinyemi , Smith, D Max , Scott, Stuart A. , Whirl‐Carrillo, Michelle

Mayo Clinic

Clinical Pharmacology & Therapeutics | June 5, 2025 | Volume: 118 | Issue: 4 | Pages: 778-789

10.1002/cpt.3736 | PMID 40468601 Get It

Barriers to incorporating pharmacogenetics into routine clinical practice in the United States are well documented. Initial surveys by the Clinical Pharmacogenetics Implementation Consortium (CPIC) in 2009 and 2010 identified barriers across four key domains that have hindered the widespread adoption of clinical pharmacogenetic testing. These are presented verbatim as: (i) absence of a definition of the processes required to interpret genotype information and to translate genetic information into clinical actions; (ii) need for recommended drug/gene pairs to implement clinically now; (iii) clinician resistance to consider pharmacogenetic information at the bedside; and (iv) concerns about test costs and reimbursement. Over time, many of these challenges have been overcome, and clinical pharmacogenetic testing has subsequently reached broader implementation. Despite this progress, several barriers remain that block further adoption. This narrative review used authors' expertise and experience to identify and describe current barriers to pharmacogenetic implementation across seven domains in the United States: equity and inclusion; guidelines and supporting evidence; regulatory agency oversight; payer coverage and insurance; availability of quality pharmacogenetic tests; electronic health records; and provider and patient education. Within each domain, it revisits past successes and challenges and explores remaining barriers. We also propose solutions to address ongoing challenges across these domains, including further expansion of recommendations beyond pharmacogenetic‐specific guidelines, standards for designing clinical decision support tools, and broader pharmacogenetics education. Addressing these remaining obstacles directs work to enable broader adoption of clinical pharmacogenetic implementation to ultimately improve patient outcomes.
Hyperinsulinemia-induced upregulation of adipocyte TPH2 contributes to peripheral serotonin production, metabolic dysfunction, and obesity
Park, Brian I., Reeves, Andrew R., Wilson, Robin A. , Fernandes, Sophia C., Buhman, Kimberly K. , Lytle, Kelli A. , Jensen, Michael D. , Greenberg, Andrew S. , Park, Brian I., Reeves, Andrew R., Zhu, Ying , Fernandes, Sophia C., Jensen, Michael

Mayo Clinic

Journal of Clinical Investigation | June 4, 2025 | Volume: 135 | Issue: 14 | Pages: No page available

10.1172/jci190765 | PMID 40455408 Get It

Tryptophan hydroxylase (TPH) is a rate-limiting enzyme for serotonin or 5-hydroxytryptamine (5-HT) synthesis. Previously, adipocyte TPH1 has been linked to increased adipose 5-HT, reduced brown adipose tissue (BAT) thermogenesis, and obesity. However, the role of TPH2, a neural isoform highly expressed in obese adipose tissue, is unknown. Here, we report that adipose tissue expression of TPH2 is dramatically elevated in mice with diet-induced obesity (DIO) and ob/ob mice, as well as in obese humans. In mice fed a high-fat diet, adipocyte TPH2 deficiency improved DIO-induced metabolic complications, enhanced BAT thermogenesis, and increased intestinal energy-harvesting efficiency without affecting adiposity. Conversely, TPH2 overexpression in epididymal adipocytes of chow-fed mice raised adipose and plasma 5-HT levels, suppressed BAT thermogenesis, and exacerbated obesity and metabolic dysfunction. We found that obesity-induced hyperinsulinemia upregulated adipocyte TPH2 expression via activation of mechanistic target of rapamycin complex 1 and SREBP1. In humans, TPH2 mRNA levels in subcutaneous adipose tissue, but not those of TPH1 , are positively correlated with fasting plasma insulin concentrations. In summary, our study demonstrates that obesity-associated increases in adipocyte TPH2 can regulate distal tissue physiology and energy metabolism, suggesting that TPH2 could be a potential therapeutic target for obesity and its associated complications.
Novel mouse model reveals neurodevelopmental origin of PMM2-CDG brain pathology
Edmondson, Andrew C. , Xia, Zijie , Melendez-Perez, Ashley, Cai, Cadmus, Collins, Ashley M., Shiplett, Emily J. , Hill, Sophie F. , Somarowthu, Ala , Dam, Jacques Van, Pai, Ling-Lin, Santi, Mariarita , He, Miao , Radenkovic, Silvia , Hill, Sophie F , Edmondson, Andrew C , Budhraja, Rohit , Xia, Zijie, Melendez-Perez, Ashley J. , Cai, Cadmus, Dam, Johanna, Kim, Seonhee , He, Miao, Goldberg, Ethan M. , Kozicz, Tamás , Morava, Éva , Pandey, Akhilesh , Zhou, Zhaolan

Mayo Clinic

No container title available | June 4, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.01.657261 | PMID 40501776 Get It

Abstract Congenital disorders of glycosylation (CDG) are a group of neurogenetic conditions resulting from disruptions in the cellular glycosylation machinery. The majority of CDG patients have compound heterozygous pathogenic variants in the phosphomannomutase 2 ( PMM2) gene. Individuals with PMM2-CDG exhibit multi-systemic symptoms, prominently featuring neurological deficits with nearly all patients exhibiting cerebellar hypoplasia and ataxia. To overcome embryonic lethality caused by whole body knock-out of Pmm2 and mimic patient-related compound heterozygous pathogenic variants, we paired a Pmm2 flox allele ( Pmm2 fl ) with a catalytically inactive knock-in allele ( Pmm2 R137H ), commonly present in PMM2-CDG patients. Mice with post-mitotic loss of PMM2 from neurons or astrocytes are indistinguishable from unaffected littermates, including in a broad battery of neurological assessments. In contrast, removal of PMM2 from embryonic neural precursor cells leads to cerebellar hypoplasia, ataxia, seizures, and early lethality. Comprehensive multi-omics profiling, including metabolomics, glycomics, single-cell transcriptomics, proteomics, and glycoproteomics, reveal widespread molecular disturbances throughout the brain, with the cerebellum showing the most pronounced disruption. These findings highlight the heightened dependency of the developing cerebellum on intact N-glycosylation, aligning with clinical observations in PMM2-CDG patients. Importantly, glycoproteomic alterations identified in our mouse model are corroborated in PMM2-CDG patient post-mortem cerebellar tissue, underscoring the translational relevance of our findings and implicating impaired synaptic transmission as a key pathogenic mechanism.
Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study
Ailawadhi, Sikander , Spencer, Andrew , Lu, Jin , Oriol, Albert , Ling, Silvia , Schjesvold, Fredrik , Berkovits, Alejandro, Li, Chunrui , Rajnics, Péter , Custidiano, Maria Del Rosario, Parmar, Gurdeep , Leleu, Xavier , Gómez, César Cinesi, Mateos, María‐Victoria , Buck, Tondre T., Minařík, Jiří , Goldschmidt, Hartmut , Zhang, Rick, Sémiond, Dorothée, Suzan, Florence, Stefanova-Urena, Maya, Koch, Victorine, Spencer, Andrew , Oriol, Albert , Ling, Silvia , Schjesvold, Fredrik H , Hus, Marek , Li, Chun-Rui , Dimopoulos, Meletios A , Hungria, Vania , Custidiano, Maria Del Rosario , Leleu, Xavier , Cerchione, Claudio , Ishida, Tadao , Mateos, María-Victoria , Minařík, Jiří , Goldschmidt, Hartmut , Moreau, Philippe , Ailawadhi, Sikander , Špıčka, Ivan , Dimopoulos, Meletios Α. , Beşışık, Sevgi Kalayoğlu , Hungria, Vânia , Li, Fei , Gomez, Cesar, LeBlanc, Richard , Koch, Victorine, Moreau, Philippe

Mayo Clinic

Journal of Clinical Oncology | June 3, 2025 | Volume: 43 | Issue: 22 | Pages: 2527-2537

10.1200/jco-25-00744 | PMID 40459178 Get It

PURPOSE To report the results of the multicenter, open-label IRAKLIA trial (ClinicalTrials.gov identifier: NCT05405166 ) of isatuximab subcutaneous (SC) versus intravenous (IV), plus pomalidomide and dexamethasone, in relapsed/refractory multiple myeloma (MM), to our knowledge, the first phase III MM trial using an on-body injector (OBI). METHODS Patients with ≥1 prior line of therapy were randomly assigned 1:1 to Isa OBI (1,400 mg) or IV (10 mg/kg) once weekly in cycle (C)1 and then every 2 weeks, plus pomalidomide (4 mg once daily, day [D]1-21) and dexamethasone (40 mg once weekly [age ≥75: 20 mg]) and treated until progression, unacceptable toxicity, or patient request. Coprimary end points were overall response rate (ORR; noninferiority margin, 0.839) and Isa C trough (C6D1 predose; noninferiority margin, 0.8). Noninferiority of OBI versus IV was demonstrated if both coprimary end points achieved noninferiority. RESULTS IRAKLIA randomly assigned 531 patients (OBI, n=263; IV, n=268). After 12-month median follow-up, the ORR was 71.1% (OBI) and 70.5% (IV; relative risk, 1.008 [95% CI, 0.903 to 1.126]; lower CI exceeded noninferiority margin). The mean (standard deviation) C6D1 C trough was 499 (259) μg/mL (OBI) and 340 (169) μg/mL (IV). The C trough geometric mean ratio (90% CI) was 1.532 (1.316 to 1.784); lower CI exceeded noninferiority margin. Grade ≥3 treatment-emergent adverse event incidences were 81.7% (OBI) and 76.1% (IV); infusion reaction incidences were 1.5% and 25.0%. Injection site reactions occurred in 0.4% of OBI injections (all grade 1-2); 99.9% of injections completed without interruption. CONCLUSION IRAKLIA demonstrated efficacy and pharmacokinetic noninferiority between Isa OBI and IV. No unexpected safety signal was observed, with excellent local tolerability of Isa OBI. Efficacy and safety were comparable with Isa IV in ICARIA-MM, except the lower OBI infusion reaction rate. These results support potential use of the OBI, designed to improve practice efficiency.
Evaluation of Bioprosthetic Valve Dysfunction in the SMART Randomized Clinical Trial
Herrmann, Howard C. , Blackman, Daniel J. , Attizzani, Guilherme F. , Abdel‐Wahab, Mohamed , Batchelor, Wayne , Gillam, Linda D. , Rogers, Toby , Oh, Jae K. , Althouse, Andrew D. , Mehran, Roxana , Tchétché, Didier , Batchelor, Wayne B , Mehran, Roxana , Herrmann, Howard C , Gillam, Linda D

Mayo Clinic

Circulation: Cardiovascular Interventions | June 2, 2025 | Volume: 18 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.015202 | PMID 40452601 Get It

Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Babiker, Hani M. , Picozzi, Vincent J. , Chandana, Sreenivasa R , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gállego, Javier , Bullock, Andrea J. , Chunyi, Hao, Hitre, Erika, Osipov, Arsen , Alés, Inmaculada, Dragovich, Tomislav, Lee, Woo Jin , Feeney, Kynan, Ueno, Makoto , Seufferlein, Thomas , Investigators, on behalf of the PANOVA-3 Study, Osipov, Arsen, Matrana, Marc , Blondin, Nicholas, Shroff, Rachna T. , Orr, Douglas, Anderson, Michael J. , Shields, Anthony F. , Hamm, John , Bullock, Andrea, Nagireddy, Sumana, Kolodney, Joanna, Dragovich, Tomislav, Maniam, Ajit, Sears, Judith D., Stilwill, Joseph, Cusnir, Mike , Niewiaroska, Anna, Small, William, Kasi, Anup, Tache, Jason, Ross, Sharona, Shihabi, Samer, Gandhi, Sunil, Reeves, J. N. , Green, Garrett , Feinstein, Trevor, Huyck, Timothy K., Ramdin, Nadia, Marsh, Robert , Jiang, Yixing , Hatoum, Hassan , Manda, Sudhir, Kochenderfer, Mark D., Illum, Henrik, Richards, Donald , Valilis, P., Wong, Lucas, Newton, Herbert B. , Abdelrahim, Maen, Einspahr, David, Siegel, Richard, McKenney, Scott, Narang, Mohit , Cárdenes, Higinia R. , Thanikachalam, Kannan , Raff, Joshua P. , Ye, Joseph , Behl, Deepti , Kam, Audrey E., DeRose, Paul, Tasneem, A. , Brenner, Warren, Santos, Jennifer De Los , Rausch, D C, Trikha, Gaurav, Gabrail, Nashat , Mowat, Rex B., Jahangir, Khawaja, Schumaker, Robert P. , Soffen, Edward , Bravin, Eric, Gupta, Mukul Kumar , Bedoya-Apraez, Ivan Dario, Kang, Tyler Y., Lemay, Frédéric , Vincent, Mark , Létourneau, Richard, Doehring, Christine, Haberkorn, Mike, Rußwurm, Karen, Chater, Jack, Küng, Marc , Schacher, Sabine, Passhak, Maria , Geva, Ravit , Hubert, Ayala, Golan, Talia , Senellart, Hélène, Trouilloud, Isabelle , Blan, Jean-Frederic, Dourthe, Luis-Marie, Roy, Florence Le, Martin-Babau, J., Greil, Richard , Schreil, Georg, Gerger, Armin , Eisterer, Wolfgang , Mercadé, T. Macarulla, Cubillo, Antonio , Pons, Francesc Valladares, Díaz, Inmaculada Alés, Rivera, Fernando , Sarvise, Mariano Ponz, Airoldi, Mario , Bellotti, Giovanna, Corsi, Domenico , Antonuzzo, Lorenzo , Melichar, Bohuslav, Holečková, Petra , Kotasek, Rostislav, Němeček, Radim , Cutsem, Eric van, Laethem, Jean‐Luc Van , Sym, Sun Jin , Kim, Jin Young , Oh, Sang Cheul , Park, Joon Oh, Kim, Jin Won , Lee, Myung Ah , Choi, Hye Jin, Kang, Seok Yun , Mruk, Andrzej, Freier, Beata, Kosakowska, Ewa Anna, Kocsis, Judit, Csőszi, Tibor , Hitre, Erika, Al-Farhat, Yousuf, Cang, Shundong , Jin, Gang , Zuo, Changzeng, Song, Lijie, Wu, Zheng , Gao, Jie , Zhang, Tao� , Wang, Yusheng , Yuan, Xin , Li, Zhi-Hua , Chen, Rufu , Cai, Xiujun , Zhu, Zhizhen, Bai, Yuxian , Bai, Chunmei, Yau, Thomas, Joubert, Warren , Wong, Ka Yeung Mark, Harris, Marion , Mišir, Ana, Faccio, Adilson , Cruz, Felipe Melo , Azevedo, Srergio De, Victorino, Ana Paula , Paiva, Tadeu Ferreira, Franke, Fábio , Tiscoski, Katsuki Arima , Parolla, Gabriel, Lilno, Flora, Siqueira, Mariana Bruno , Lyra, Marcos, Lira, Jose Luis Martinez, Oliva, Dolores Mendoza, Vazquez, Arturo, Luviano, Jesus Elvis Cabrera, Gutiérrez, Erika Castillo , Camargo, Vanessa Rosas, Guerra, Cristian Chavez, Flores, Osvaldo Hernandez, Contreras, Jessica Reyes, Villanueva, Ángel Gómez, Villanueva, Omar Zayas, Bullock, Andrea , Wyrwicz, Lucjan , Osipov, Arsen , De La Fouchardiere, Christelle , Lee, Woojin , Ueno, Makoto , Van Cutsem, Eric , Macarulla, Teresa , Babiker, Hani , Antonuzzo, Lorenzo , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gallego, Javier , Hitre, Erika, Fouchardière, Christelle de la , Dragovich, Tomislav, Philip, Philip A. , Cutsem, Eric Van , Macarulla, Teresa , Investigators, on behalf of the PANOVA-3 Study, Spigel, David R. , Osipov, Arsen, Lou, Emil , Bullock, Andrea, Dragovich, Tomislav, Coveler, Andrew L. , Arena, Francis P. , Kasi, Anup, Ross, Sharona , Reeves, James, Green, Garrett, Uemura, Marc Isamu , Ye, Joseph, Wang, James Z. , Rausch, Daniel, Park, Jae‐Hyun , Schumaker, Robert, Gupta, Mukul, Letourneau, Richard, Fuchs, Martin , Vogel, Arndt , Chater, Jack, Schacher, Sabine, Stemmer, Salomon M. , Dourthe, Luis-Marie, Abdelghani, Méher Ben , Pons, Francesc Valladares, Guillén‐Ponce, Carmen , Yayá, Ricardo , Ponz‐Sarvisé, Mariano , Vincenzi, Bruno , Melichar, Bohuslav, Petruzelka, Lubos B. , Cutsem, Eric van, Borbath, Ivan , Hwang, Jun‐Eul , Oh, Sung Yong , Lee, Moon Hee , Choi, Hye Jin , Chon, Hong Jae , Ramlau, Rodryg , Mruk, Andrzej, Hitre, Erika, Bassam, Ali, Hao, Chunyi , Liang, Bo , Li, Wei , Bai, Chunmei , Joubert, Warren, Marx, Gavin M. , Azevedo, Srergio De, Hoff, Paulo M. , Vazquez, Arturo, Guerra, Cristian Chavez, Cortez, David Orta, Campos-Gómez, Saúl , Espinoza, Iván Romarico González

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2350-2360

10.1200/jco-25-00746 | PMID 40448572 Get It

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC). METHODS In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle with or without TTFields. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR). Distant PFS was analyzed post hoc. RESULTS OS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0] v 14.2 months [95% CI, 12.8 to 15.4]; hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.99]; P = .039). PFS, local PFS, and ORR were not improved. Pain-free survival was significantly prolonged with TTFields with gemcitabine/nab-paclitaxel (median, 15.2 months [95% CI, 10.3 to 22.8] v 9.1 months [95% CI, 7.4 to 12.7]; HR, 0.74 [95% CI, 0.56 to 0.97]; P = .027), as was distant PFS (median, 13.9 months [95% CI, 12.2 to 16.8] v 11.5 months [95% CI, 10.4 to 12.9]; HR, 0.74 [95% CI, 0.57 to 0.96]; P = .022). Device-related skin adverse events (AEs) were experienced by 76.3% of patients. Most device-related skin AEs were mild to moderate, with 7.7% of patients reporting a grade 3 AE. CONCLUSION This study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.
Phase II (Alliance A091802) Randomized Trial of Avelumab Plus Cetuximab Versus Avelumab Alone in Advanced Cutaneous Squamous Cell Carcinoma
Zandberg, Dan P. , Allred, Jacob B., Rosenberg, Ari J. , Swiecicki, Paul , Julian, Ricklie , Poklepovic, Andrew , Bauman, Jessica R. , Saba, Nabil F. , Rivera, Edgardo, Rowland, Kendrith M. , Cordes, Julia, Münster, Pamela N. , Swiecicki, Paul Loren , Poklepovic, Andrew S , Bauman, Jessica R , Saba, Nabil F , Davar, Diwakar , Ho, Alan L , Berg, Stephanie A , Schwartz, Gary K , Munster, Pamela , Kaczmar, John M. , Phan, Minh D., Davar, Diwakar , Cordes, Julia, Ho, Alan L. , Zhang, Miao , Berg, Stephanie , Schwartz, Gary K.

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2398-2408

10.1200/jco-25-00759 | PMID 40448574 Get It

PURPOSE Continued improvement in outcomes is needed for advanced cutaneous squamous cell carcinoma (cSCC). Methods Alliance A091802 is a randomized phase II trial of avelumab (800 mg IV once every 2 weeks) plus cetuximab (500 mg/m 2 IV once every 2 weeks) versus avelumab alone once every 2 weeks for up to 2 years. Cetuximab was given for 1 year in the avelumab + cetuximab arm. Crossover at progression to avelumab + cetuximab was allowed. Randomization was 1:1, stratified by PD-L1 and HIV status. Patients had distant metastatic or unresectable locally advanced cSCC, were anti–PD-1/PD-L1 monoclonal antibody–naive, had no previous cetuximab in the advanced setting, had an Eastern Cooperative Oncology Group performance status of 0-2, and could be HIV+ (CD4 >200, viral load <200). Patients with chronic lymphocytic leukemia, immunosuppression, or active autoimmune diseases were excluded. The primary end point was progression-free survival (PFS; null hypothesis: median = 12 months v alternative hypothesis: 21 months or a 75% improvement, power of 80% with one-sided alpha .2, n = 57, 37 PFS events required). Secondary end points were overall survival, objective response rates (ORRs), clinical benefit rate, and toxicity. RESULTS Sixty patients were enrolled; 57 patients were evaluable. The median age was 72 years, all were HIV–; 75.4% was PD-L1+, 84.2% had head/neck origin, 47.4% had distant metastasis, and there were no differences in baseline characteristics by arm. Avelumab + cetuximab significantly improved PFS versus avelumab (median, 11.1 [7.6-not reached (NR)] v 3.0 months [2.7-13.6] hazard ratio, 0.48 [95% CI, 0.23 to 0.97], P = .018). Avelumab patients who crossed over (n = 9) to combination had a median PFS after crossover of 11.3 months (5.8-NR). The confirmed ORR was 27.6% with avelumab + cetuximab and 21.4% with avelumab. Grade 3 treatment-related adverse events occurred in 48.3% and 21.5% of patients with avelumab + cetuximab (most common: rash [20.7%], infusion reaction [20.7%]) and avelumab, respectively. CONCLUSION Avelumab + cetuximab significantly improved PFS versus avelumab alone in patients with advanced cSCC. Alliance A091802 supports a larger confirmatory study with the combination of cetuximab and PD-1:PD-(L)1 blockade.